Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Vinayak Viplav"'
Autor:
Aditya Kumar Bubna, Vinayak Viplav
Publikováno v:
Dermatology Practical & Conceptual, Vol 14, Iss 3 (2024)
Introduction: Guselkumab is an interleukin 23p19 inhibitor, and the first in this group, to be approved by the US Food and Drug Administration (FDA) for the management of moderate to severe psoriasis. Apart from its utility in psoriasis, there are a
Externí odkaz:
https://doaj.org/article/0e52cf094e1a40679fb98588fbf8de44